FDA Panel Leans Toward Including CYP2D6 Dx in Tamoxifen Label, But is Split on Language
November 15, 2006
FDA Panel Leans Toward Including CYP2D6 Dx in Tamoxifen Label, But is Split on Language
The Pharmaceutical Science Clinical Pharmacology Subcommittee was split over whether the label should “recommend” the genetic test or make it an “option” for health care providers and patients to discuss.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- GenMark Lowers Revenue Guidance after NMT, Luminex Deal
June 17, 2013 / GenomeWeb Daily News - Exact Sciences Files for Public Offering of Stock
June 17, 2013 / GenomeWeb Daily News - UCSC Designing Social Network-type Model for Analyzing Cancer Data
June 17, 2013 / GenomeWeb Daily News - Atossa Signs on Third PPO for Breast Cancer Test
June 17, 2013 / GenomeWeb Daily News - Arrays Increasingly Adopted for Stillbirth Studies, though Questions about Cost, Counseling Remain
June 17, 2013 / BioArray News